French health tech company Volta Medical, which developed an AI-enabled software for interventional cardiac electrophysiology, garnered €36 million ($37.8 million) in Series B funding, bringing its total raise to €70 million ($73.6 million).
U.S.-based Vensana Capital led the round, with co-investment from Lightstone Ventures and Glide Healthcare.
Volta offers its FDA-cleared XV1 AI-enabled software that helps physicians identify and treat complex cardiac arrhythmias, such as atrial fibrillation. The company will use the money to support product development, clinical trials, U.S. commercialization and regulatory approvals.
“Volta Medical’s technology is designed to redefine how electrophysiologists make real-time decisions in pinpointing areas relevant to atrial fibrillation persistence,” Dr. Justin Klein, cofounder and managing partner of Vensana Capital, said in a statement. “We applaud the team’s commitment to validating their products with an investment in multiple high quality clinical trials. We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”
AI-enabled cancer care platform Onc.AI closed $25 million in Series A funding, co-led by Action Potential Venture Capital and MassMutual.
Life Extension Ventures and existing investors Accomplice, Blue Venture Fund, KdT Ventures and Digitalis Ventures also participated in the round.
The company creates products that utilize multimodal AI predictions and real-world datasets to help with cancer treatment decisions.
“Onc.AI’s novel platform, which leverages radiomics and deep learning, has the potential to improve medical oncologist clinical decision-making and to meaningfully advance pharma immuno-oncology research and clinical trials,” Juan-Pablo Mas of Action Potential Venture Capital, said in a statement. “APVC is excited to support the team’s efforts in establishing a leadership position in this emerging category.”
Porter announced it raised $5.4 million in seed funding led by Old Line Capital, Grit Capital Partners and JLC Family Office.
The AI-enabled care coordination company helps its members navigate the healthcare ecosystem and access resources for at-home care. Porter will use the seed funds to grow its business.
“Porter’s combination of care coordination with strong data analytics and coverage insights, gives the company massive credibility with members. The company’s deep understanding of risk adjustment and the payor ecosystem got us excited to invest in the disruptive alignment of interests that the platform brings to payors and consumers,” Paul Palmieri, managing partner at Grit Capital Partners, said in a statement.
KeyCare, maker of a virtual care platform built with the Epic EHR, announced it received an additional $3 million in Series A investment, bringing its total Series A raise to $27 million.
The additional funds came from Ziegler and two additional health systems, joining previous investors 8VC, LRVHealth, Bold Capital and Spectrum Health Ventures.
“With the completion of our Series A funding, KeyCare is well-positioned to continue the optimization of our platform and provide virtual care services to additional health system partners,” Dr. Lyle Berkowitz, CEO of KeyCare, said in a statement. “It’s gratifying to have the support of strategic investors like Ziegler, as well as our health system partners. And we are excited that multiple new health systems are scheduled to go live in the first quarter of 2023 while our pipeline for additional health systems and virtual care partners continues to grow.”